03:52 , Dec 15, 2017 |  BC Week In Review  |  Company News

BioPharma Credit gets BMS diabetes royalties

Debt investor BioPharma Credit plc (LSE:BPCR) acquired from Royalty Pharma (New York, N.Y.) half of its royalty streams on sales of diabetes products including Onglyza saxagliptin (BMS-477118, OPC-262) and Farxiga/Forxiga dapagliflozin. Royalty Pharma acquired the...